Is propranolol safe for use during pregnancy?

Propranolol Safety in Pregnancy

Propranolol can be used during pregnancy when medically necessary, but should be avoided in the first trimester if possible, initiated at the lowest effective dose, and requires close fetal monitoring for growth restriction and bradycardia throughout pregnancy. 1, 2

Evidence-Based Safety Classification

• The FDA classifies propranolol as Pregnancy Category C, meaning animal studies show adverse effects but there are no adequate well-controlled studies in pregnant women 3
• Multiple cardiology societies (American Heart Association, American College of Cardiology, European Society of Cardiology) consider propranolol a relatively safe first-line beta-blocker when beta-blockade is medically necessary during pregnancy 1, 2, 4
• Propranolol has a longer safety record compared to other beta-blockers and is preferred over atenolol, which is FDA Category D and should never be used in pregnancy 1, 2

Primary Fetal Risks

Intrauterine growth retardation (IUGR) is the most significant concern:

• Growth restriction has been documented in multiple studies, particularly with first-trimester exposure and prolonged therapy 1, 2, 3, 5
• The FDA label explicitly states that "intrauterine growth retardation, small placentas, and congenital abnormalities have been reported in neonates whose mothers received propranolol during pregnancy" 3
• However, the risk is substantially lower than with atenolol, which causes more pronounced growth retardation and is contraindicated 1, 2

Neonatal complications at delivery:

• Bradycardia, hypoglycemia, and respiratory depression may occur in neonates at birth 1, 2, 3, 6
• These effects are not inevitable and prospective randomized studies have failed to demonstrate higher incidence compared to placebo 1
• The FDA mandates that "adequate facilities for monitoring such infants at birth should be available" 3

Clinical Management Algorithm

Step 1: Assess Medical Necessity

• Use propranolol only when the maternal benefit clearly justifies the fetal risk 3
• For mild symptoms in structurally normal hearts, provide reassurance rather than pharmacologic therapy 1
• Antiarrhythmic therapy should be reserved for intolerable symptoms or hemodynamic compromise 1

Step 2: Timing Considerations

• Avoid first-trimester exposure whenever possible because this period carries the greatest teratogenic risk 1, 2, 4
• If treatment is essential, continuation into second and third trimesters is acceptable 1, 2
• The European Society of Cardiology specifically recommends that "beta-blocking agents should not be taken in the first trimester, if possible" 1

Step 3: Dosing Strategy

• Initiate at the lowest effective dose (typically 10-40 mg for situational use or 80-160 mg daily divided for chronic prophylaxis) 2, 4
• Titrate according to clinical response rather than using fixed high doses 2, 4
• Use scheduled (regular) dosing rather than as-needed dosing for chronic conditions to maintain stable plasma concentrations 2

Step 4: Required Fetal Monitoring

• Serial ultrasound for fetal growth every 4 weeks during second and third trimesters to detect IUGR early 2, 4
• Fetal echocardiography and surveillance for bradycardia, particularly when hemodynamic load is highest in later pregnancy 2, 4
• More intensive monitoring than routine prenatal care is mandatory 2, 4

Step 5: Neonatal Preparation

• Ensure delivery occurs at a facility with adequate neonatal monitoring capabilities 3
• Prepare for potential neonatal bradycardia, hypoglycemia, and respiratory support 2, 4
• Arrange early follow-up after hospital discharge 7

Critical Pitfalls to Avoid

Never use atenolol during pregnancy:

• Atenolol is FDA Category D and causes more pronounced IUGR than propranolol 1
• The European Society of Cardiology states "atenolol should not be used for any arrhythmia" during pregnancy 2
• Later studies specifically documented growth retardation and higher preterm delivery rates with first-trimester atenolol 1

Do not assume all beta-blockers are equivalent:

• Selective β1 agents (metoprolol) are theoretically preferable because they interfere less with peripheral vasodilation and uterine relaxation 1
• Metoprolol is considered equally safe and may be an alternative if growth concerns arise 1, 2

Avoid methyldopa for urgent blood pressure reduction:

• While methyldopa has long-term infant outcome data, it should not be used primarily for urgent BP reduction 1
• Labetalol IV and oral nifedipine are preferred first-line agents for hypertensive emergencies 1

Postpartum and Breastfeeding

• Propranolol is considered safe during breastfeeding with minimal infant exposure through breast milk 1, 2, 4, 8
• The maximum dose likely ingested by an infant is approximately 0.1% of the maternal dose 8
• Propranolol remains the first-choice beta-blocker for the postpartum period if continued treatment is needed 4

Nuances in the Evidence

The 2025 Circulation hypertension guideline prioritizes nifedipine and labetalol as first-line agents for hypertension in pregnancy, with propranolol not specifically mentioned for this indication 1. However, for arrhythmia management, the 2003 ACC/AHA/ESC guidelines give propranolol a Class IIa recommendation for prophylactic therapy of supraventricular tachycardia 1. This reflects that propranolol's role is primarily for cardiac arrhythmias and specific conditions (migraine, anxiety, variceal bleeding prophylaxis) rather than routine hypertension management 2.

The FDA label emphasizes that animal studies at high doses showed embryotoxicity and neonatal deaths, but notes that "no evidence of embryo or neonatal toxicity was noted" in rabbit studies at equivalent doses 3. This underscores the importance of using the lowest effective dose in humans.